Tesamorelin's growth-hormone-releasing-hormone activity and the boundary between research material and approved medicine.
Tesamorelin is a growth-hormone-releasing-hormone analog that engages the GHRH receptor and stimulates the endogenous growth-hormone and IGF-1 axis.
Established research and approval context
Randomized clinical trials studied tesamorelin in people with HIV-associated abdominal fat accumulation. FDA-approved Egrifta products contain tesamorelin for a specific HIV-lipodystrophy indication and include defined formulations, manufacturing controls, warnings, and limitations.
Research material boundary
A Platinum Bio Labs tesamorelin vial is not an Egrifta product and is not represented as sterile, pharmaceutical-grade, approved, or suitable for administration. The clinical literature cannot establish the identity, safety, or equivalence of a third-party reference material.
Sources
Research-use notice: For laboratory research use only. Not for human or veterinary use, ingestion, injection, therapeutic, diagnostic, or clinical use. This educational material summarizes research context; it is not medical advice and does not establish safety, efficacy, identity, purity, or suitability for any use.